MX2018007225A - Terapia combinada para el cancer. - Google Patents
Terapia combinada para el cancer.Info
- Publication number
- MX2018007225A MX2018007225A MX2018007225A MX2018007225A MX2018007225A MX 2018007225 A MX2018007225 A MX 2018007225A MX 2018007225 A MX2018007225 A MX 2018007225A MX 2018007225 A MX2018007225 A MX 2018007225A MX 2018007225 A MX2018007225 A MX 2018007225A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- patient
- compound
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un método para tratar cánceres histológicos de células escamosas, cáncer de mama, cáncer de próstata, cáncer de vejiga, cáncer cervical, cáncer de endometrio, cáncer de ovario y cáncer colorrectal en un paciente que comprende la administración a un paciente que necesita de dicho tratamiento de una cantidad eficaz de un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo; en combinación con una cantidad eficaz de un compuesto de la fórmula (II) o una sal farmacéuticamente aceptable del mismo. (ver Fórmulas).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267462P | 2015-12-15 | 2015-12-15 | |
| PCT/US2016/065503 WO2017105982A1 (en) | 2015-12-15 | 2016-12-08 | Combination therapy for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007225A true MX2018007225A (es) | 2018-08-01 |
Family
ID=57590897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007225A MX2018007225A (es) | 2015-12-15 | 2016-12-08 | Terapia combinada para el cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180228795A1 (es) |
| EP (1) | EP3389660B1 (es) |
| JP (1) | JP6359197B2 (es) |
| KR (1) | KR20180081580A (es) |
| CN (1) | CN108472293A (es) |
| AU (1) | AU2016370297A1 (es) |
| BR (1) | BR112018011203A2 (es) |
| CA (1) | CA3005358A1 (es) |
| EA (1) | EA201891005A1 (es) |
| HK (1) | HK1254687A1 (es) |
| IL (1) | IL259097A (es) |
| MX (1) | MX2018007225A (es) |
| NZ (1) | NZ742470A (es) |
| SG (1) | SG11201803903YA (es) |
| WO (1) | WO2017105982A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| RU2627841C2 (ru) * | 2010-11-16 | 2017-08-14 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US20140314791A1 (en) * | 2012-01-05 | 2014-10-23 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
-
2016
- 2016-12-08 MX MX2018007225A patent/MX2018007225A/es unknown
- 2016-12-08 SG SG11201803903YA patent/SG11201803903YA/en unknown
- 2016-12-08 JP JP2017538245A patent/JP6359197B2/ja not_active Expired - Fee Related
- 2016-12-08 EP EP16816563.7A patent/EP3389660B1/en active Active
- 2016-12-08 KR KR1020187016468A patent/KR20180081580A/ko not_active Ceased
- 2016-12-08 EA EA201891005A patent/EA201891005A1/ru unknown
- 2016-12-08 US US15/513,189 patent/US20180228795A1/en not_active Abandoned
- 2016-12-08 AU AU2016370297A patent/AU2016370297A1/en not_active Abandoned
- 2016-12-08 CN CN201680073762.1A patent/CN108472293A/zh active Pending
- 2016-12-08 CA CA3005358A patent/CA3005358A1/en not_active Abandoned
- 2016-12-08 WO PCT/US2016/065503 patent/WO2017105982A1/en not_active Ceased
- 2016-12-08 BR BR112018011203A patent/BR112018011203A2/pt not_active Application Discontinuation
- 2016-12-08 HK HK18113669.3A patent/HK1254687A1/zh unknown
- 2016-12-08 NZ NZ74247016A patent/NZ742470A/en not_active IP Right Cessation
-
2018
- 2018-05-02 IL IL259097A patent/IL259097A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3389660B1 (en) | 2019-10-16 |
| BR112018011203A2 (pt) | 2018-11-21 |
| CA3005358A1 (en) | 2017-06-22 |
| EA201891005A1 (ru) | 2018-12-28 |
| NZ742470A (en) | 2019-09-27 |
| AU2016370297A1 (en) | 2018-05-24 |
| US20180228795A1 (en) | 2018-08-16 |
| EP3389660A1 (en) | 2018-10-24 |
| CN108472293A (zh) | 2018-08-31 |
| HK1254687A1 (zh) | 2019-07-26 |
| JP2018502873A (ja) | 2018-02-01 |
| IL259097A (en) | 2018-06-28 |
| SG11201803903YA (en) | 2018-06-28 |
| KR20180081580A (ko) | 2018-07-16 |
| WO2017105982A1 (en) | 2017-06-22 |
| JP6359197B2 (ja) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| ZA201607488B (en) | Compounds for treating brain cancer | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| EP4656246A3 (en) | Combination therapies for the treatment of cancer | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| MD20170073A2 (ro) | Terapii combinate pentru tratarea cancerelor | |
| MX368286B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
| GEAP202114756A (en) | Combination therapy for the treatment of cancer | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| MX2020001727A (es) | Terapia de combinacion. | |
| IL281439A (en) | Combined treatment for blood cancer | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| IL279277A (en) | In vivo controlled combination therapy for treatment of cancer | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| IL279591A (en) | Cancer treatment methods using combination therapy | |
| SG11202000881VA (en) | Adjuvant therapy for use in prostate cancer treatment | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| NZ742470A (en) | Combination therapy for cancer | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |